Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

Hakim, J., Musiime, V., Szubert, A.J., et al.

This multi-country trial examined outcomes among treatment-naïve adults and children with CD4 counts below 100 who were given enhanced antimicrobial prophylaxis including trimethoprim-sulfamethoxazole, isoniazid-pyridoxine, fluconazole, azithromycin, and albendazole in addition to antiretroviral therapy (ART). Among the 1,806 patients enrolled in the trial, 906 were randomized to the enhanced prophylaxis group and 899 were randomized to the standard prophylaxis group. At 12 weeks, patients in the enhanced prophylaxis group reported lower adherence to prophylaxis, but adherence at 24 and 48 weeks was similar between the groups. ART adherence was also similar in both groups. At 24 weeks, 8.9 percent of patients in the enhanced prophylaxis group had died, compared to 12.2 percent in the standardized prophylaxis group. At 48 weeks, 11 percent of patients in the enhanced prophylaxis group had died, versus 14.4 percent in the standardized prophylaxis group. This translated to a 27 percent and 24 percent reduction in death rates at 24 and 48 weeks, respectively. Participants in the enhanced prophylaxis group experienced significantly fewer hospitalization days, deaths, World Health Organization stage 3 or 4 occurrences, new tuberculosis diagnoses, and cryptococcal or candidiasis infections. There were also fewer immune reconstitution inflammatory events. The authors concluded that enhanced prophylaxis offers increased survival rates, has a low pill burden, is relatively low cost, has few side effects, and is easily implemented.

September 11, 2017
Year of publication
2017
Resource types
Journal and research articles
Countries
Tags
treatment-naïve, antimicrobial prophylaxis, antiretroviral therapy (ART), adherence, Uganda, Zimbabwe, Malawi, Kenya, HIV-related morbidity, co-infections, tuberculosis, TB, cryptococcus

Similar Resources

Option B+ for prevention of mother-to-child transmission (PMTCT) specifies treating all HIV-positive women with antiretroviral therapy (ART) regardless of CD4 count. This simplified approach enhances countries' capacity to reach national HIV targets and contribute to the global 90-90-90 goals.…

The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that of HIV-negative people. However, little is known about how these populations compare in terms of health-related quality of life (HRQoL).

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences. We conducted in-depth interviews with 43 PLHIV…

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences.

To understand the uptake of HIV services by adolescent women, the authors conducted a retrospective analysis of patient-level data (2011–2013) on services for antenatal care (ANC) and prevention of mother-to-child transmission (PMTCT) in 36 facilities in 5 districts in Zimbabwe.

Female sex workers (FSW) in sub-Saharan Africa have a higher prevalence of HIV than other women of reproductive age. Social, legal, and structural barriers influence their access to care. Little is known about the HIV diagnosis and care cascade in most countries in southern Africa.

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

This study aimed to evaluate the impact of clinic-based prevention of mother-to-child transmission (PMTCT) community support by trained lay health workers in addition to standard clinical care on PMTCT infant outcomes.

Malawi, like other countries with a generalized HIV epidemic, is striving to reach the ambitious targets set by UNAIDS known as the three 90's for testing, provision of antiretroviral therapy and viral suppression.